Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance. Management expects a rebound in Q2 with resumed full manufacturing capacity and increased commercial infusions, potentially leading to a positive earnings surprise. Despite the Q1 setback, Iovance's early adoption, expanding treatment network, and international regulatory prospects indicate strong long-term growth potential.
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Brian Gastman - EVP, Medical Affairs Conference Call Participants Andrew Tsai - Jefferies Tyler Van Buren - TD Cowen Salim Syed - Mizuho Andrea Newkirk - Goldman Sachs Yanan Zhu - Wells Fargo Colleen Kusy - Baird Peter Lawson - Barclays Reni Benjamin - Citizens Operator Good day and thank you for standing by. Welcome everyone to the Iovance Biotherapeutics First Quarter 2025 Financial Results Conference Call.
14 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
7 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
14 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
7 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
26 Feb 2025 Date | | - Cons. EPS | - EPS |
7 Nov 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Frederick G. Vogt CEO | XBER Exchange | US4622601007 ISIN |
US Country | 838 Employees | - Last Dividend | 26 Sep 2013 Last Split | 15 Oct 2010 IPO Date |
Iovance Biotherapeutics, Inc. stands as a commercial-stage biotechnology entity dedicated to developing and commercializing innovative cell therapies. Utilizing autologous tumor infiltrating lymphocyte technology, the company aims to provide treatments for metastatic melanoma alongside other solid tumor cancers within the United States. Originating in 2007 and originally known as Lion Biotechnologies, Inc., the company transitioned to its current name in June 2017. With its headquarters in San Carlos, California, Iovance Biotherapeutics has established numerous strategic collaborations and licensing agreements with prominent institutions and companies across the healthcare and biotechnology sectors. These partnerships extend to WuXi Advanced Therapies, Inc.; National Institutes of Health; National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH, aiming to enhance its offering and impact in cancer treatment.
Described as a pioneering tumor-derived autologous T cell immunotherapy, Amtagvi is specifically designed for adult patients struggling with unresectable or metastatic melanoma. This product marks Iovance's commitment to offering advanced therapeutic options that leverage the body's immune system to fight cancer.
An interleukin-2 product, Proleukin serves as a treatment solution for patients with metastatic renal cell carcinoma. Through boosting the patient's immune response, it aims at attacking and eliminating cancer cells, underscoring the company's expertise in immunotherapy.
This development focuses on treating frontline advanced melanoma patients by combining lifileucel with pembrolizumab. The strategic integration of these treatments exemplifies Iovance's innovative approach towards providing comprehensive care for melanoma patients.
Targeted at addressing the challenges in non-small cell lung cancer (NSCLC) and other solid tumor cancers, LN-145 is an ongoing project that aims to expand the therapeutic reach of the company’s immunotherapy solutions.
Currently in Phase 1/2 IOV-GM1-201 clinical trial, IOV-4001 represents Iovance's commitment to innovating treatment options for NSCLC. This exploration into new therapies highlights the company’s dedication to contributing significant advancements in cancer treatment.
Another pivotal area of development, the application of lifileucel for treating gynecological cancers, signifies Iovance's broader endeavor to tackle a variety of cancer types with its cell therapy technologies.